Promestriene

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Promestriene
Accession Number
DB12487
Type
Small Molecule
Groups
Investigational
Description

Promestriene has been used in trials studying the prevention of Hypospadias.

Synonyms
Not Available
Categories
UNII
GXM4PER6WZ
CAS number
39219-28-8
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Promestriene.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Promestriene.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Promestriene.Experimental, Illicit
AbciximabPromestriene may decrease the anticoagulant activities of Abciximab.Approved
AcenocoumarolPromestriene may decrease the anticoagulant activities of Acenocoumarol.Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Promestriene.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Promestriene.Experimental, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Promestriene.Experimental, Investigational
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Promestriene.Approved
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Promestriene.Approved, Investigational
AncrodPromestriene may decrease the anticoagulant activities of Ancrod.Investigational
AndrostenedioneThe serum concentration of Androstenedione can be increased when it is combined with Promestriene.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Promestriene.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be increased when it is combined with Promestriene.Investigational
Anthrax immune globulin humanPromestriene may increase the thrombogenic activities of Anthrax immune globulin human.Approved
Antithrombin III humanPromestriene may decrease the anticoagulant activities of Antithrombin III human.Approved
ApixabanPromestriene may decrease the anticoagulant activities of Apixaban.Approved
ArdeparinPromestriene may decrease the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanPromestriene may decrease the anticoagulant activities of Argatroban.Approved, Investigational
AtamestaneThe serum concentration of Atamestane can be increased when it is combined with Promestriene.Investigational
BecaplerminPromestriene may decrease the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Promestriene.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Promestriene.Approved, Vet Approved
BivalirudinPromestriene may decrease the anticoagulant activities of Bivalirudin.Approved, Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Promestriene.Approved
Capromab pendetidePromestriene may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CelecoxibCelecoxib may increase the thrombogenic activities of Promestriene.Approved, Investigational
CertoparinPromestriene may decrease the anticoagulant activities of Certoparin.Approved, Investigational
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Promestriene.Approved
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Promestriene.Approved, Investigational
Citric AcidPromestriene may decrease the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Promestriene.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Promestriene.Approved
ClobetasoneThe serum concentration of Clobetasone can be increased when it is combined with Promestriene.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Promestriene.Approved
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Promestriene.Investigational
CorticosteroneThe serum concentration of Corticosterone can be increased when it is combined with Promestriene.Experimental
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Promestriene.Approved
Dabigatran etexilatePromestriene may decrease the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinPromestriene may decrease the anticoagulant activities of Dalteparin.Approved
DanaparoidPromestriene may decrease the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanPromestriene may decrease the anticoagulant activities of Darexaban.Investigational
DeflazacortThe serum concentration of Deflazacort can be increased when it is combined with Promestriene.Approved, Investigational
DesirudinPromestriene may decrease the anticoagulant activities of Desirudin.Approved
DesonideThe serum concentration of Desonide can be increased when it is combined with Promestriene.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Promestriene.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Promestriene.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Promestriene.Experimental, Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Promestriene.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Promestriene.Vet Approved
DextranPromestriene may decrease the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Promestriene may decrease the anticoagulant activities of Dextran 40.Approved
Dextran 70Promestriene may decrease the anticoagulant activities of Dextran 70.Approved
Dextran 75Promestriene may decrease the anticoagulant activities of Dextran 75.Approved
DicoumarolPromestriene may decrease the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Promestriene.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Promestriene.Approved, Investigational, Withdrawn
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Promestriene.Approved
Edetic AcidPromestriene may decrease the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanPromestriene may decrease the anticoagulant activities of Edoxaban.Approved
EnoxaparinPromestriene may decrease the anticoagulant activities of Enoxaparin.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Promestriene.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Promestriene.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Promestriene.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Promestriene.Approved
Ethyl biscoumacetatePromestriene may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the thrombogenic activities of Promestriene.Approved, Investigational, Vet Approved
EtoricoxibEtoricoxib may increase the thrombogenic activities of Promestriene.Approved, Investigational
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Promestriene.Approved, Investigational
Ferulic acidPromestriene may decrease the anticoagulant activities of Ferulic acid.Experimental
FluasteroneThe serum concentration of Fluasterone can be increased when it is combined with Promestriene.Investigational
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Promestriene.Approved
FluindionePromestriene may decrease the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Promestriene.Approved, Vet Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Promestriene.Approved, Investigational
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Promestriene.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Promestriene.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Promestriene.Approved, Withdrawn
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Promestriene.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Promestriene.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Promestriene.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Promestriene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Promestriene.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Promestriene.Approved
FondaparinuxPromestriene may decrease the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumPromestriene may decrease the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Promestriene.Approved, Investigational, Withdrawn
GabexatePromestriene may decrease the anticoagulant activities of Gabexate.Investigational
HalcinonideThe serum concentration of Halcinonide can be increased when it is combined with Promestriene.Approved, Investigational, Withdrawn
HE3286The serum concentration of HE3286 can be increased when it is combined with Promestriene.Investigational
HeparinPromestriene may decrease the anticoagulant activities of Heparin.Approved, Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Promestriene.Approved, Investigational
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Promestriene.Approved, Vet Approved
IdraparinuxPromestriene may decrease the anticoagulant activities of Idraparinux.Investigational
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Promestriene.Investigational
LenalidomidePromestriene may increase the thrombogenic activities of Lenalidomide.Approved
LepirudinPromestriene may decrease the anticoagulant activities of Lepirudin.Approved
LetaxabanPromestriene may decrease the anticoagulant activities of Letaxaban.Investigational
LoteprednolThe serum concentration of Loteprednol can be increased when it is combined with Promestriene.Approved
LumiracoxibLumiracoxib may increase the thrombogenic activities of Promestriene.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Promestriene.Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Promestriene.Approved
MelagatranPromestriene may decrease the anticoagulant activities of Melagatran.Experimental
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Promestriene.Vet Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Promestriene.Approved, Vet Approved
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Promestriene.Approved, Vet Approved
NabumetoneNabumetone may increase the thrombogenic activities of Promestriene.Approved
NadroparinPromestriene may decrease the anticoagulant activities of Nadroparin.Approved
NafamostatPromestriene may decrease the anticoagulant activities of Nafamostat.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Promestriene.Investigational
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Promestriene.Investigational
OspemifeneThe risk or severity of adverse effects can be increased when Promestriene is combined with Ospemifene.Approved
OtamixabanPromestriene may decrease the anticoagulant activities of Otamixaban.Investigational
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Promestriene.Approved
ParecoxibParecoxib may increase the thrombogenic activities of Promestriene.Approved
Pentaerythritol TetranitratePromestriene may decrease the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfatePromestriene may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
PhenindionePromestriene may decrease the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonPromestriene may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Promestriene.Approved, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be increased when it is combined with Promestriene.Investigational
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Promestriene.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Promestriene.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Promestriene.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Promestriene.Experimental, Investigational
Protein CPromestriene may decrease the anticoagulant activities of Protein C.Approved
Protein S humanPromestriene may decrease the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydePromestriene may decrease the anticoagulant activities of Protocatechualdehyde.Approved
ReviparinPromestriene may decrease the anticoagulant activities of Reviparin.Approved, Investigational
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Promestriene.Approved
RivaroxabanPromestriene may decrease the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the thrombogenic activities of Promestriene.Investigational, Withdrawn
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Promestriene.Approved, Investigational
SomatotropinThe therapeutic efficacy of Somatotropin can be decreased when used in combination with Promestriene.Approved, Investigational
SulodexidePromestriene may decrease the anticoagulant activities of Sulodexide.Approved, Investigational
ThalidomidePromestriene may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
TipranavirPromestriene may increase the dermatologic adverse activities of Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Promestriene.Approved, Withdrawn
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Promestriene.Approved, Vet Approved
TroxerutinPromestriene may decrease the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe serum concentration of Ulobetasol can be increased when it is combined with Promestriene.Approved
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Promestriene.Approved, Investigational
ValdecoxibValdecoxib may increase the thrombogenic activities of Promestriene.Investigational, Withdrawn
Vitamin CThe serum concentration of Promestriene can be increased when it is combined with Vitamin C.Approved, Nutraceutical
WarfarinPromestriene may decrease the anticoagulant activities of Warfarin.Approved
XimelagatranPromestriene may decrease the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911337
ATC Codes
G03CA09 — Promestriene

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedPreventionHypospadias1
4CompletedSupportive CareAtrophic Vaginitis / Endometrial Hyperplasia / Pelvic Organ Prolapse (POP)1
4Not Yet RecruitingTreatmentVulvovaginal Atrophy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 20, 2016 16:34 / Updated on November 06, 2017 06:46